We are proud to announce that LDG GmbH (Laboratories Dr. Gansauge) has been awarded the Global 100 – 2025 Award in the Biotechnology & Life Sciences category. This prestigious international recognition highlights our pioneering role in developing dendritic cell-based therapies, an innovative approach that empowers the immune system to fight cancer naturally and effectively.

Founded by Prof. Dr. Frank Gansauge, LDG has established itself as a leader in personalised cancer immunotherapy with its proprietary LANEX-DC® vaccine. Unlike conventional treatments, our approach trains the patient's own immune system to recognise and destroy cancer cells while sparing healthy tissue. To date, more than 3,500 patients worldwide have benefited from this therapy, with encouraging results across a wide range of cancers including melanoma, pancreatic, kidney, and ovarian cancers.

The Global 100 award underscores our dual commitment to scientific innovation and patient-centred care. Every treatment is tailored to the individual, supported by our state-of-the-art GMP-certified laboratories and an experienced medical team dedicated to achieving the highest standards of safety, precision, and compassion. By combining innovation with a focus on the patient's unique needs, we continue to shape the future of cancer care.

As we look ahead, LDG remains dedicated to advancing immunotherapy research, expanding access to LANEX-DC® worldwide, and building on our mission to offer hope and better outcomes to patients facing difficult diagnoses. This award is both a recognition of the lives we have touched and an inspiration to keep pushing the boundaries of science and care.